Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 2/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23731045 | 0.82 | ADORA2A (0.41) | XDHHPRT1CDK1CCNB1CCNE1 | |
| SCHEMBL2385929 | 0.82 | HPRT1 (0.55) | XDHHPRT1CDK1CCNB1CCNE1 | |
| SCHEMBL10104854 | 0.80 | XDH (0.46) | XDHHPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL19413462 | 0.80 | ADORA2A (0.49) | XDHHPRT1CDK1CCNB1CCNE1 | |
| SCHEMBL21127824 | 0.75 | HPRT1 (0.54) | XDHHPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL21311450 | 0.73 | HPRT1 (0.56) | XDHHPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL6455102 | 0.73 | HPRT1 (0.56) | XDHHPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL24709220 | 0.73 | HPRT1 (0.53) | XDHHPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL20782353 | 0.71 | HPRT1 (0.51) | XDHHPRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL22083751 | 0.71 | HPRT1 (0.54) | XDHHPRT1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8575119-B2 | 2′-chloroacetylenyl substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | XDH 193/4885HPRT1 14/4885CDK1 52/4885 |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | NME2, HAVCR2, ENTPD5 | XDH 225/4885HPRT1 61/4885CDK1 25/4885 |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | XDH 356/4885HPRT1 85/4885CDK1 3/4885 |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | DUT, HAVCR2, HCCS | XDH 266/4885HPRT1 33/4885CDK1 118/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | XDH 193/4885HPRT1 14/4885CDK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.